Fate Therapeutics Inc (FATE) - Total Liabilities

Latest as of September 2025: $109.61 Million USD

Based on the latest financial reports, Fate Therapeutics Inc (FATE) has total liabilities worth $109.61 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Fate Therapeutics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.

Fate Therapeutics Inc - Total Liabilities Trend (2011–2024)

This chart illustrates how Fate Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see FATE current and non-current assets.

Fate Therapeutics Inc Competitors by Total Liabilities

The table below lists competitors of Fate Therapeutics Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Capral Ltd AU:CAA	Australia	AU$239.10 Million
Donpon Precision TWO:3290	Taiwan	NT$2.37 Billion
MEDIFAST INC NYSE:MED	USA	$64.02 Million
Origin Property PCL BK:ORI	Thailand	฿42.79 Billion
Unicycive Therapeutics Inc NASDAQ:UNCY	USA	$18.76 Million
Shriram Properties Limited NSE:SHRIRAMPPS	India	Rs-14.60 Billion
Surteco Group SE XETRA:SUR	Germany	€572.82 Million
Koleksiyon Mobilya Sanayi AS IS:KLSYN	Turkey	TL1.41 Billion

Liability Composition Analysis (2011–2024)

This chart breaks down Fate Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Fate Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	7.87	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.47	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.32	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Fate Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Fate Therapeutics Inc (2011–2024)

The table below shows the annual total liabilities of Fate Therapeutics Inc from 2011 to 2024.

Year	Total Liabilities	Change
2024-12-31	$121.97 Million	-11.49%
2023-12-31	$137.80 Million	-37.82%
2022-12-31	$221.62 Million	-8.65%
2021-12-31	$242.62 Million	+1.93%
2020-12-31	$238.01 Million	+313.80%
2019-12-31	$57.52 Million	+9.43%
2018-12-31	$52.56 Million	+87.04%
2017-12-31	$28.10 Million	+28.36%
2016-12-31	$21.89 Million	-26.82%
2015-12-31	$29.92 Million	+30.86%
2014-12-31	$22.86 Million	+382.87%
2013-12-31	$4.74 Million	-92.59%
2012-12-31	$63.90 Million	+9.17%
2011-12-31	$58.53 Million	--

About Fate Therapeutics Inc

NASDAQ:FATE USA Biotechnology

Market Cap

$291.84 Million

Market Cap Rank

#18239 Global

#4268 in USA

Share Price

$2.53

Change (1 day)

+0.40%

52-Week Range

$0.96 - $3.11

All Time High

$117.40